Medicortex Finland Is Developing Therapeutic Drugs and Diagnostic Tools for Traumatic Brain Injury
MediCortex is currently seeking investors and has launched a crowd funding in order to develop therapeutic drugs for Traumatic Brain Injury, TBI, and to identify biomarkers to reliably evaluate the extent and severity of brain injury.
MediCortex Finland, a start-up pharmaceutical company focused on the treatment of neurodegenerative conditions, is developing therapeutic drugs which will limit the long-term effects of brain injury, including the types of severe brain trauma that veterans have received in combat. Another mission for the company is to identify biomarkers and a test to reliably establish the severity and extent of a brain injury.
Medicortex is working towards the identification of brain injury biomarkers and their incorporation into a quick and accurate diagnostic kit that can be used by all healthcare professionals with ease. The ideal kit will not only diagnose the presence of brain injury, it will also quantify its severity and indicate the precise treatment needed. In addition, the kit could become a key component of efficacy testing in all future clinical trials on TBI.
MediCortex was founded by Dr. Adrian Harel in 2014 in Turku, Finland, and operates as a privately owned company. Dr. Harel has a track record in leadership of early-stage drug discovery companies and business management. MediCortex Finland, currently in the proof-of-concept stage, is seeking an investment to support synthesis and initial in-vitro tissue culture studies for assessing the biological activity and lack of toxicity of its pipeline compounds. The company has launched a crowd funding campaign accessible at http://privatequity.biz/stock/medicortex-finland-oy/
Adrian Harel, Ph.D., MBA
Itäinen Pitkäkatu 4 B, 4. krs
Tel: +358 (0) 46 611 3988
Editor’s note: The views and opinions expressed in the articles contained in the International NeuroTrauma Letter are those of the authors and contributors alone and do not necessarily reflect the views, policy or position of the International Brain Injury Association or all members of the INTL Editorial Board. The INTL is provided solely as an informational resource and the inclusion of any particular article does not establish or imply IBIA’s endorsement of its contents.